Navigation Links
YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
Date:6/29/2009

MISSISSAUGA, ON, June 29 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that YM's subsidiary, CIMYM BioSciences Inc. and Oncoscience AG have resolved the issues between the companies in a cooperative effort. CIMYM BioSciences has formally notified Oncoscience that it no longer intends to submit its application to the London Court of International Arbitration for resolution of the matters previously in dispute.

"We are pleased that CIMYM BioSciences and Oncoscience have resolved their differences amicably at a minimal cost to either party and that each are committed to cooperate fully in moving nimotuzumab forward clinically with all due deliberate speed," said David Allan, Chairman and CEO of YM BioSciences. "The late-stage European clinical program Oncoscience is undertaking contributes significantly to the broad program being advanced by the network of cooperative relationships dedicated to the development of this important cancer drug globally."

"Its unique safety profile and efficacy make nimotuzumab a very promising and innovative treatment option with the potential to maintain a high quality of life for patients suffering from a number of different cancer indications," added Ferdinand Bach, CEO of Oncoscience. "I am delighted that we may now focus our combined resources exclusively on the contribution to the clinical program being undertaken globally for this promising drug. Recruitment of our Phase III trial in newly diagnosed pediatric pontine glioma has been concluded and we anticipate that recruitment in our randomised Phase III trial in adult glioblastoma grade IV will be completed in 2009. We are confident that data from these tri
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Proove Biosciences , the ... presenting research on the association between specific genes and ... Psychiatric and Mental Health Congress’ 27th Annual Scientific ... on the theme of ‘Embracing Change.’ Mental health, and ... landscape. From the challenges presented by the Affordable Care ...
(Date:9/23/2014)... San Jose, California (PRWEB) September 23, 2014 ... – Agricultural biotechnology is gaining steady popularity the ... sophisticated plant breeding techniques. Growth in the marketplace ... Genetically Modified (GM) crops in developing countries. Several ... 30% of under-nourished population, have already implemented genetically ...
(Date:9/23/2014)... This is a professional and ... Isopropanol (IPA) industry. The report provides a basic ... industry chain structure. Global market analysis and Chinese ... on history, developments, trends and competitive landscape of ... Chinese situation is also offered. , The report ...
(Date:9/23/2014)... Marktech Optoelectronics has introduced the MTE280xxx series, its ... 280 nm wavelength range. This series joins Marktech’s current ... to 405nm. These new devices are suitable for applications ... Mark Campito, Marktech’s CEO states that “what makes this ... that we offer it in one of the largest ...
Breaking Biology Technology:Proove Biosciences Will Be Exhibiting New Genetic Research at the 27th Annual US Psych Congress Scientific Program 2Proove Biosciences Will Be Exhibiting New Genetic Research at the 27th Annual US Psych Congress Scientific Program 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 2(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 3Marktech Introduces its New Line of Deep UV Emitters 2
... Split Effective at Close of Business Today ... - VGNI Stock Symbol to Change to VRGE, PLANTATION, ... majority-owned subsidiary,of Viragen, Inc. (OTC Bulletin Board: VRAI), today announced that ... outstanding common stock,will become effective at the close of business today, ...
... 4, Dow AgroSciences LLC, a wholly owned subsidiary,of ... and Exelixis Plant Sciences, a,wholly owned subsidiary of ... the companies have signed a major research collaboration ... Dow AgroSciences,affiliate Agrigenetics Inc. The agreement is focused ...
... forum for the global pharma/biotech industries, Pharmaceutical Manufacturing and Biotechnology Middle ... ... DUBAI, United Arab Emirates, Sept. 4 The Middle East,market for pharmaceutical ... growth in double digits. The market,drivers are: -- Dubai is the ...
Cached Biology Technology:Viragen International to Reverse Split Its Common Stock 2Viragen International to Reverse Split Its Common Stock 3Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 2Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 3
(Date:9/23/2014)... National Institutes of Health will award funds to support ... Screening program to improve ways of predicting drug safety ... refine existing 3-D human tissue chips and combine them ... functions of the human body. Led by the National ... support 11 institutions at $17 million in 2014 with ...
(Date:9/23/2014)... announced today that the Company has secured $21 million ... be used to expand the Company,s cancer immunotherapy pipeline ... investor Yuan Capital led the round, with participation from ... Ventures, Suma Venture and Harbinger Venture Capital. , ... fully-human antibodies engineered to mimic the functions of a ...
(Date:9/23/2014)... are the same ones that were used 50 years ago. ... disease, which causes nearly 25 million people in the United ... best to take a deep breath. , But finding ... what works for one person doesn,t necessarily work for another, ... candidates often fail to mimic human responses costing tremendous ...
Breaking Biology News(10 mins):NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3
... a great health threat, especially since routine smallpox ... treatment currently exists. In the February 1 issue ... and colleagues from Harvard Medical School propose a ... of signaling mediated by the smallpox growth factor ...
... research on prions, the infectious proteins behind "mad cow" disease ... prions in one species to infect other species depends on ... prion. Two studies on the topic appear in the 8 ... suggests that prions from one species rarely infect other species, ...
... tweaked to absorb more contaminants, researchers found that the ... results raised hopes that the plants might become a ... new research findings, published Feb. 1 in the journal ... of the Indian mustard plant, Brassica juncea, absorbed two ...
Cached Biology News:Fibril Shape Is The Basis Of Prion Strains And Cross-species Prion Infection 2Fibril Shape Is The Basis Of Prion Strains And Cross-species Prion Infection 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 2Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 4
Recombinant Rat Leptin, Ultra Pure...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
Biology Products: